213971-34-7
213971-34-7
Chemical Structure
FX-11
Synonym(s): LDHA Inhibitor FX11
- CAS No.: 213971-34-7
- Formula:C22H22O4
- Molecular Weight:350.41
IUPAC Name: 7-benzyl-2,3-dihydroxy-6-methyl-4-propyl-1-naphthoic acid
InChIKey: LVPYVYFMCKYFCZ-UHFFFAOYSA-N
SMILES: O=C(C1=C2C=C(CC3=CC=CC=C3)C(C)=CC2=C(CCC)C(O)=C1O)O
Biological Activity: FX-11 is a potent, selective, reversible and competitive lactate dehydrogenase A (LDHA) inhibitor, with a Ki of 8 μM. FX-11 reduces ATP levels and induces oxidative stress, ROS production and cell death. FX-11 shows antitumor activity in lymphoma and pancreatic cancer xenografts[1][2][3].
| Cat. No. | 상품명 | Purity | 제품 설명 | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
FX-11 | 99.26% | FX-11 is a potent, selective, reversible and competitive lactate dehydrogenase A (LDHA) inhibitor, with a Ki of 8 μM. FX-11 reduces ATP levels and induces oxidative stress, ROS production and cell death. FX-11 shows antitumor activity in lymphoma and pancreatic cancer xenografts. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
FX-11 (Standard) | ≥98% | FX-11 (Standard) is the analytical standard of FX-11 (HY-16214). This product is intended for research and analytical applications. FX-11 is a potent, selective, reversible and competitive lactate dehydrogenase A (LDHA) inhibitor, with a Ki of 8 μM. FX-11 reduces ATP levels and induces oxidative stress, ROS production and cell death. FX-11 shows antitumor activity in lymphoma and pancreatic cancer xenografts. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. EC Calvaresi. Small molecule inhibitors of lactate dehydrogenase a as an anticancer strategy. 2014.
- [2]. Le A, et, al. Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc Natl Acad Sci U S A. 2010 Feb 2;107(5):2037-42. [Content Brief]
- [3]. Mohammad GH, et al. Targeting Pyruvate Kinase M2 and Lactate Dehydrogenase A Is an Effective Combination Strategy for the Treatment of Pancreatic Cancer. Cancers (Basel). 2019 Sep 16;11(9):1372. [Content Brief]
